MeiraGTx Names Immunovant’s Zeldin as Its Chief Medical Officer

Robert Zeldin has joined gene therapy developer MeiraGTx (NASDAQ: [[ticker:MGTX]]) as its chief medical officer. Most recently he held the same role at Immunovant (NASDAQ: [[ticker:IMVT]]). Prior Zeldin served as CMO at Acceleron Pharma (NASDAQ: [[ticker:XLRN]]) and at Ablynx. His experience also includes time at Stallergenes, Novartis (NYSE: [[ticker:NVS]]), and Merck, as well as a stint with the FDA prior to entering industry.

MeiraGTx, of New York and London, recently began planning a Phase 3 trial for one of its clinical-stage programs, a potential treatment for an inherited condition that causes progressive vision loss it is developing with partner Johnson & Johnson (NYSE: [[ticker:JNJ]]).

Author: Sarah de Crescenzo

Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register. She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine.